NCT06295809 2025-12-09
INTerpath-007
Merck Sharp & Dohme LLC
Phase 2/3 Active not recruiting
Clinical Trials
3 trialsNCT06947928 2025-10-14
Placebo-Controlled Trial of IFx-Hu2.0 Followed By Pembrolizumab In Checkpoint Inhibitor Naïve Participants With Advanced Or Metastatic Merkel Cell Carcinoma
TuHURA Biosciences, Inc.
Phase 2/3 Recruiting
NCT00367042 2015-04-16
Study to Determine if Tissue Scored With a Scalpel Results in Any Noticeable Marks
University of California, Davis
Phase 2/3 Completed